{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:15:30Z","timestamp":1788538530921,"version":"build-2803163510"},"reference-count":14,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,11,23]],"date-time":"2012-11-23T00:00:00Z","timestamp":1353628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Stiefel, a GSK company"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2012,12]]},"abstract":"Summary<\/jats:title>Background<\/jats:title>Topical combination therapy, such as that with fixed\u2010dose clindamycin\/benzoyl peroxide (BPO<\/jats:styled-content>) or adapalene\/BPO<\/jats:styled-content>, is the recommended first\u2010line approach for the treatment of facial acne.<\/jats:p><\/jats:sec>Aims<\/jats:title>To compare the tolerability of clindamycin 1%\/BPO<\/jats:styled-content> 5% gel vs<\/jats:italic>. adapalene 0.1% BPO<\/jats:styled-content> 2.5% gel for the first 2\u00a0weeks of treatment in patients with facial acne.<\/jats:p><\/jats:sec>Patients\/Methods<\/jats:title>Using a randomized, single\u2010blind, split\u2010face method, 48 patients with acne received both clindamycin\/BPO<\/jats:styled-content> and adapalene\/BPO<\/jats:styled-content> once daily for 2\u00a0weeks. The primary endpoint was investigator\u2010assessed tolerability. Treatment efficacy, patient\u2010assessed tolerability and satisfaction, and safety were also investigated.<\/jats:p><\/jats:sec>Results<\/jats:title>Forty\u2010five patients completed treatment. Investigator\u2010rated scores for erythema, dryness, and peeling were significantly higher with adapalene\/BPO<\/jats:styled-content> than clindamycin\/BPO<\/jats:styled-content>. Patients rated clindamycin\/BPO<\/jats:styled-content> as significantly more tolerable than adapalene\/BPO<\/jats:styled-content> for redness, dryness, burning, itching, and scaling. Investigator Static Global Assessment scores and lesion counts improved with both products, with no significant difference between treatments. Patients' Global Change Assessment showed a statistically significant difference in favor of clindamycin\/BPO<\/jats:styled-content> at week 1, but not week 2. Overall, >80% of patients were \u201csatisfied\u201d or \u201cvery satisfied\u201d with treatment at week 2, but 63% of patients stated that they preferred clindamycin\/BPO<\/jats:styled-content>. Both products were well tolerated, with no serious adverse events (AE<\/jats:styled-content>s), but a post hoc<\/jats:italic> analysis indicated that treatment\u2010related AE<\/jats:styled-content>s, including irritation, dryness and erythema, were significantly less common with clindamycin\/BPO<\/jats:styled-content>.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Clindamycin\/BPO<\/jats:styled-content> had a better tolerability profile than adapalene\/BPO<\/jats:styled-content> during 2\u00a0weeks of split\u2010face treatment. Treatment satisfaction was highest with clindamycin\/BPO<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.12013","type":"journal-article","created":{"date-parts":[[2012,11,23]],"date-time":"2012-11-23T10:42:27Z","timestamp":1353667347000},"page":"251-260","source":"Crossref","is-referenced-by-count":19,"title":["The tolerability profile of clindamycin 1%\/benzoyl peroxide 5% gel vs. adapalene 0.1%\/benzoyl peroxide 2.5% gel for facial acne: results of a randomized, single\u2010blind, split\u2010face study"],"prefix":"10.1111","volume":"11","author":[{"given":"Pablo","family":"Gonzalez","sequence":"first","affiliation":[{"name":"Buenos Aires Skin Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Vila","sequence":"additional","affiliation":[{"name":"Stiefel, a GSK company Sao Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Cirigliano","sequence":"additional","affiliation":[{"name":"Stiefel, a GSK company Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,11,23]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.01.019"},{"issue":"2","key":"e_1_2_7_3_1","first-page":"4","article-title":"Changing the face of acne therapy","volume":"83","author":"Ghali F","year":"2009","journal-title":"Cutis"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.06.006"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/0128071-200809060-00003"},{"key":"e_1_2_7_6_1","first-page":"625","article-title":"A comparative review of the efficacy and tolerability of retinoid\u2010containing combination regimens for the treatment of acne vulgaris","volume":"6","author":"Campbell JL","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_7_1","first-page":"641","article-title":"Facial tolerability of topical retinoid therapy","volume":"3","author":"Leyden J","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903277228"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08308.x"},{"key":"e_1_2_7_10_1","first-page":"223","article-title":"Study of the efficacy, tolerability, and safety of 2 fixed\u2010dose combination gels in the management of acne vulgaris","volume":"84","author":"Zouboulis CC","year":"2009","journal-title":"Cutis"},{"key":"e_1_2_7_11_1","first-page":"131","article-title":"A randomized, investigator\u2010blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%\/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%\/tretinoin 0.025% gel in the topical treatment of acne vulgaris","volume":"9","author":"Jackson JM","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38987.606701.80"},{"key":"e_1_2_7_13_1","first-page":"265","article-title":"Comparison of 2 clindamycin 1%\u2010benzoyl peroxide 5% topical gels used once daily in the management of acne vulgaris","volume":"83","author":"Dhawan SS","year":"2009","journal-title":"Cutis"},{"key":"e_1_2_7_14_1","first-page":"605","article-title":"How patients experience and manage dryness and irritation from acne treatment","volume":"10","author":"Feldman SR","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.03.014"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjocd.12013","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjocd.12013","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.12013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T11:04:34Z","timestamp":1697367874000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.12013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,23]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1111\/jocd.12013"],"URL":"https:\/\/doi.org\/10.1111\/jocd.12013","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,23]]}}}